Pre-Made Corifollitropin Alfa Biosimilar, Fusion Protein targeting FSHR fused with CTP (C-terminal peptide of hCG): Recombinant therapeutic protein targeting FSHRO/LGR1/ODG1 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Corifollitropin Alfa Biosimilar, Fusion Protein targeting FSHR fused with CTP (C-terminal peptide of hCG): Recombinant therapeutic protein targeting FSHRO/LGR1/ODG1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gonadotropin preparations are drugs that mimic the physiological effects of gonadotropins, used therapeutically mainly as fertility medication for ovarian hyperstimulation and ovulation induction. For example, the so-called menotropins consist of LH and FSH extracted from human urine from menopausal women.[1] There are also recombinant variants.
Corifollitropin alfa (Elonva?) is the first hybrid follicle-stimulating hormone (FSH) molecule with demonstrated sustained follicle-stimulating activity. Corifollitropin combines follicle stimulating hormone with part of the human chorionic gonadotropin molecule. This extends the time to peak serum concentration and approximately doubles the half-life for the treatment of infertility.
| Products Name (INN Index) | Pre-Made Corifollitropin Alfa Biosimilar, Fusion Protein targeting FSHR fused with CTP (C-terminal peptide of hCG): Recombinant therapeutic protein targeting FSHRO/LGR1/ODG1 |
|---|---|
| INN Name | corifollitropin alfa |
| Target | FSHR |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – Follicle- stimulating hormone (FSH) – CTP (C-terminal peptide of the ¦Â- subunit of human chorionic gonadotropin (hCG)) |
| VD LC | Fusion – Follicle- stimulating hormone (FSH) – CTP (C-terminal peptide of the ¦Â- subunit of human chorionic gonadotropin (hCG)) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Merck?&?Co.,?Inc. (Whitehouse Station NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FSHR |
| Package |
